



Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Saving? A Difference-in-Difference Analysis of 14 Countries

Hyunjung Woo¹ · Gyeongseon Shin¹ · Donghwan Lee² · Hye-Young Kwon³ · SeungJin Bae¹

Published online: 22 January 2024
© The Author(s) 2024

Correction to: BioDrugs

<https://doi.org/10.1007/s40259-023-00636-z>

Declarations section: The Funding statement that previously read

Funding This work was supported by the National Research Foundation (NRF-2021R1F1A10502).

should read

Funding This work was supported by the National Research Foundation (NRF-2021R1F1A1050281).

The original article has corrected.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40259-023-00636-z>.

✉ Hye-Young Kwon
haeyoungkwon0111@gmail.com

✉ SeungJin Bae
sjbae@ewha.ac.kr

¹ College of Pharmacy, Ewha Womans University, Seoul, South Korea

² Department of Statistics, Ewha Womans University, Seoul, South Korea

³ Department of Public Health, Mokwon University, Daejeon, South Korea